Abstract | OBJECTIVE: Although body dysmorphic disorder often responds to serotonin reuptake inhibitors (SRIs), most patients do not respond or respond only partially. However, placebo-controlled studies of augmentation of SRIs have not been done. Furthermore, although 40%-50% of patients are delusional, studies of antipsychotic medications have not been done. METHOD: RESULTS:
Pimozide was not more effective than placebo: two (18.2%) of 11 subjects responded to pimozide and three (17.6%) of 17 subjects responded to placebo. There was no significant effect of baseline delusionality on endpoint severity of body dysmorphic disorder. Delusionality did not decrease significantly more with pimozide than placebo. CONCLUSIONS:
|
Authors | Katharine A Phillips |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 162
Issue 2
Pg. 377-9
(Feb 2005)
ISSN: 0002-953X [Print] United States |
PMID | 15677604
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Placebos
- Serotonin Uptake Inhibitors
- Fluoxetine
- Pimozide
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Delusions
(drug therapy, psychology)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Fluoxetine
(therapeutic use)
- Humans
- Male
- Pimozide
(therapeutic use)
- Placebos
- Psychiatric Status Rating Scales
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Somatoform Disorders
(diagnosis, drug therapy, psychology)
- Treatment Outcome
|